Hibsago Injection, Solution
Product Images NDC 0173-0941

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Hibsago (NDC 0173-0941). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bepirovirsen Sodium Chemical Structure (Hibsago Spl Graphic 01)

Chemical structure diagram of Bepirovirsen showing its detailed molecular composition with phosphorus, sodium, and nucleotide components arranged in two strands connected diagonally.*

FDA Label Image

Figure 1 (Hibsago Spl Graphic 02)

A forest plot chart showing rate differences with 95% confidence intervals comparing Hibsago to placebo across variables including overall population, two age groups, HBsAg baseline levels, and HBeAg baseline status. The plot quantifies how much Hibsago favors rate differences over placebo in each subgroup.*

FDA Label Image

Hibsago Syringes (Hibsago Spl Graphic 03)

An instructional diagram showing a subcutaneous injection device labeled with parts before and after use. The 'Before Use' section labels the gray needle cap, inspection window with medicine visible, stopper, white finger grip, and white plunger. The 'After Use' section shows the gray needle cap removed and the needle guard activated, retracting the needle into the device with the stopper in place.*

FDA Label Image

A1 (Hibsago Spl Graphic 04)

An instructional illustration showing a red sharps disposal container labeled 'Sharps Disposal Container' alongside two individually packaged syringes and a cotton ball. This image likely demonstrates safe disposal and injection preparation for subcutaneous use.*

FDA Label Image

A2 (Hibsago Spl Graphic 05)

An instructional illustration showing a hand removing a syringe from a tray, labeled with text instructing to take the syringe(s) out of the tray. The image includes an arrow indicating upward motion and a label 'A2' in the corner.*

FDA Label Image

A3 (Hibsago Spl Graphic 06)

An instructional illustration showing two syringes designed for subcutaneous injection of a solution. The image highlights where to check the expiration date labeled as "Exp: Month-Year" on the syringe. It includes a reminder to check both the expiration date and the medicine before use.*

FDA Label Image

A4 (Hibsago Spl Graphic 07)

An instructional diagram illustrating the recommended injection sites for a subcutaneous injection of Hibsago (Bepirovirsen) 150 mg/mL. The image highlights the upper outer arms, the abdomen (excluding a 2-inch area around the navel), and the front of the thighs. Specific areas are labeled for administration by caregivers or healthcare professionals versus patient or caregiver self-administration.*

FDA Label Image

A5 (Hibsago Spl Graphic 08)

An instructional illustration labeled 'A5' depicting a hand holding a gauze pad and pressing down on an orange area, demonstrating a step in subcutaneous injection site care or post-injection pressure application.*

FDA Label Image

B1 (Hibsago Spl Graphic 09)

An instructional illustration showing a hand removing a needle cap from a syringe by pulling it upward, indicated with an orange arrow pointing up and a label 'B1' in a circle.*

FDA Label Image

B2 (Hibsago Spl Graphic 10)

Illustration showing the correct technique for subcutaneous injection using a syringe at a 45-degree angle. The image depicts a hand holding a syringe with the needle angled toward another hand's skin, indicated by an orange arrow, emphasizing proper injection angle and placement.*

FDA Label Image

B3 (Hibsago Spl Graphic 11)

An instructional illustration showing a hand preparing to administer a subcutaneous injection using a syringe labeled B3. The image includes an orange arrow indicating the direction or action to be taken during the injection process.*

FDA Label Image

B4 (Hibsago Spl Graphic 12)

An instructional diagram showing hands holding a syringe-like device, with a close-up inset emphasizing that the white plunger should be fully pressed down. The image focuses on proper use or preparation of an injection device for subcutaneous administration.*

FDA Label Image

B5 (Hibsago Spl Graphic 13)

An instructional illustration showing hands demonstrating the proper technique to use a syringe, with an orange arrow indicating the direction to pull or push a component of the syringe device.*

FDA Label Image

B6 (Hibsago Spl Graphic 14)

An illustration showing two clockwise red circular arrows surrounding the label '300 mg,' next to a circle with the code 'B6.' This image likely represents a dosage or packaging symbol relevant to the product.*

FDA Label Image

Sharps Disposal Container (Hibsago Spl Graphic 15)

An illustration of a red sharps disposal container labeled "Sharps Disposal Container". The image shows two syringes above the container, indicating proper disposal of used sharps for safety and hygiene.*

FDA Label Image

Hibsago 150 mg Per mL Syringe 2 Count Carton. (Hibsago Spl Graphic 16)

Hibsago (bepirovirsen) Injection 150 mg/mL label for subcutaneous use. The label includes directions for dosing with syringes for either 150 mg or 300 mg doses, instructions to dispense the Medication Guide, and lists contents including two 1 mL single-dose prefilled syringes. The label features the GSK logo and dosing instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.